Evidence map›Paper›PMID 36559305›Full record

ArticlePharmaceutics2022

Juho Lee, Aruzhan Saparbayeva, Shwe Phyu Hlaing, Dongmin Kwak, Hyunwoo Kim, Jihyun Kim, Eun Hee Lee, Jin-Wook Yoo

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmaceutics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
3.5field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 10 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Juho LeeCollege of Pharmacy, Pusan National University, Busan 46241, Republic of Korea.ORCID 0000-0003-2831-3191
Aruzhan SaparbayevaCollege of Pharmacy, Pusan National University, Busan 46241, Republic of Korea.
Shwe Phyu HlaingCollege of Pharmacy, Pusan National University, Busan 46241, Republic of Korea.ORCID 0000-0003-0110-412X
Dongmin KwakCollege of Pharmacy, Pusan National University, Busan 46241, Republic of Korea.ORCID 0000-0002-6544-189X
Hyunwoo KimCollege of Pharmacy, Pusan National University, Busan 46241, Republic of Korea.
Jihyun KimCollege of Pharmacy, Pusan National University, Busan 46241, Republic of Korea.
Eun Hee LeeCollege of Pharmacy, Korea University, Sejong 30019, Republic of Korea.
Jin-Wook YooCollege of Pharmacy, Pusan National University, Busan 46241, Republic of Korea.ORCID 0000-0001-5216-5518
Pusan National University · KRKorea University · KR

Funding

National Research Foundation of Korea NRF-2022R1A2C2004340Pusan National University 2022 Post-Doc. Development Program
6 · The paper itself

Abstract

Polyhydroxybutyrate (PHB) has emerged as a novel material for replacing various plastics used in the medical field. However, its application as a drug-delivery carrier for colitis-targeted delivery has not been explored. In this study, we used biosynthesized PHB combined with Eudragit FS (EFS) and cyclosporine A (CSA) to develop pH-responsive controlled CSA-releasing nanoparticles (CSA-PENPs) for colitis-targeted drug delivery and demonstrated its enhanced therapeutic efficacy in a dextran sulfate sodium (DSS)-induced murine colitis model. PHB was successfully biosynthesized in the bacterium

Indexed as

colitis-targeted drug deliveryCupriavidus necatorPHB biosynthesispH-responsivepolyhydroxybutyratesustained releaseulcerative colitis

Identifiers

PMID36559305
PMCPMC9787777
OpenAlexW4311616658

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.